13 research outputs found
On manifolds supporting quasi Anosov diffeomorphisms
Let be an -dimensional manifold supporting a quasi Anosov
diffeomorphism. If then either , in which case the
diffeomorphisms is Anosov, or else its fundamental group contains a copy of
. If then contains a copy of ,
provided that the diffeomorphism is not Anosov.Comment: 5 page
Entropy-expansiveness for partially hyperbolic diffeomorphisms
We show that diffeomorphisms with a dominated splitting of the form
, where is a nonhyperbolic central bundle that
splits in a dominated way into 1-dimensional subbundles, are entropy-expansive.
In particular, they have a principal symbolic extension and equilibrium states.Comment: 15 pages, 1 figur
Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality